Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
Clene Inc. (NASDAQ: CLNN) has enrolled over 50% of participants in its Phase 2 study evaluating CNM-ZnAg, a zinc-silver ionic solution, for treating COVID-19 in Brazil. The study, with 276 planned participants, aims to determine the drug's efficacy in preventing hospitalization and achieving symptom resolution. Topline results are anticipated in 1H 2022. Clene's President emphasized the need for new therapeutic options due to ongoing virus mutations, highlighting CNM-ZnAg's potential if proven effective.
- Over 50% participant enrollment achieved in Phase 2 study for COVID-19 treatment.
- CNM-ZnAg demonstrates both antiviral and antibacterial properties.
- Topline data expected in 1H 2022, indicating timely progress in clinical trials.
- Uncertainty surrounding the efficacy of CNM-ZnAg until study results are released.
- Potential risks associated with the clinical trial outcomes affecting further development.
- Topline data is expected in 1H 2022
- Trial is evaluating acutely symptomatic, non-hospitalized COVID-19 patients in Brazil
- CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity.
SALT LAKE CITY, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced it has enrolled more than
Study participants are randomized 1:1:2 to receive either a low dose of CNM-ZnAg, a high dose of CNM-ZnAg or placebo in addition to standard supportive care. The primary endpoint of the study is the prevention of hospitalization (measured as frequency of hospital admissions) up to day 28, with a key secondary endpoint assessing time to complete symptom resolution. Topline results are expected in 1H 2022.
“Given the COVID-19 virus’ continued mutations and its impact on healthcare systems and society’s ability to fully reopen, we need additional therapeutic options in the public health arsenal. CNM-ZnAg’s antiviral activity is broadly based, and if it proves effective in this Phase 2 study, we believe it will be well positioned to advance toward a potential registration trial for COVID-19 as well as becoming a potential candidate for other viral and bacterial indications,” stated Rob Etherington, Clene’s President and CEO.
About CNM-ZnAg, a zinc and silver nanocrystal suspension
Clene’s drug candidate, CNM-ZnAg, an ionic solution of zinc and silver, is the result of a patented manufacturing process. CNM-ZnAg is being evaluated in a Phase 2 study for the treatment of COVID-19.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying cause of many neurological diseases. Our lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis (ALS) and a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” which are intended to be covered by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Clene’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clene’s control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene’s reliance on third parties to conduct drug development, manufacturing and other services; Clene’s limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in Clene’s Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Clene’s subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Media Contact
Maggie Beller
Russo Partners, LLC
Maggie.Beller@RussoPartnersLLC.com
+1-646-942-5631
Investor Contact
John Woolford
Managing Director, Westwicke
clene@westwicke.com
+1-443-213-0506
FAQ
What is Clene Inc.'s stock symbol?
What is CNM-ZnAg?
When are the results from Clene Inc.'s Phase 2 study expected?
How many participants are involved in the CNM-ZnAg study?
What are the primary endpoints of the CNM-ZnAg study?
